The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Abstract
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Singhi, E. K., Horn, L., Sequist, L. V. D., Heymach, J. V., & Langer, C. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237821 · Cited by 48
Planchard, D., Besse, B., Kim, T. M., Quoix, É., Souquet, P. J., Mazières, J., Barlési, F., Groen, H. J. M., Smit, E. F., Baik, C. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9075 · Cited by 47
Doebele, R. C., Ahn, M., Siena, S., Drilon, A. E. D. C., Krebs, M., Lin, C., de Braud, F., John, T., Tan, D. S.-W., Seto, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.239 · Cited by 47
Bevacizumab Biosimilars: Scientific Justification for Extrapolation of Indications
Melosky, B. L., Reardon, D. A., Nixon, A. B., Subramanian, J., Bair, A. H., & Jacobs, I. A. (2018) · Future Oncology · doi:10.2217/fon-2018-0051 · Cited by 44
Larkins, E. A., Scepura, B., Blumenthal, G. M., Bloomquist, E. W., Tang, S. W., Biable, M., Kluetz, P. G., Keegan, P., & Pazdur, R. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0221 · Cited by 42
Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity
Yu, P. P., Vose, J. M., & Hayes, D. F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3628 · Cited by 42
Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
Kuriyama, Y., Kim, Y. H., Nagai, H., et al. (2013) · Case Reports in Oncology · doi:10.1159/000354756 · Cited by 41
Identification of driver mutations in lung cancer: first step in personalized cancer
Planchard, D. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0263-z · Cited by 39
Planchard, D., Groen, H. J. M., Kim, T. M., Rigas, J. R., Souquet, P. J., Baik, C. S., Barlési, F., Mazières, J., Quoix, É., Curtis, C. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8006 · Cited by 31
Chalmers, A. W., Cannon, L. A., & Akerley, W. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0296 · Cited by 31
Self-citationRicciuti, B., Chiari, R., Chiarini, P., Crinò, L., Maiettini, D., Ludovini, V., & Metro, G. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0411-1 · Cited by 29
Otsuka, T., Mori, M., Yano, Y., Uchida, J., Nishino, K., Kaji, R., Hata, A., Hattori, Y., Urata, Y., Kaneda, T., et al. (2015) · PubMed · Cited by 28
Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Nosaki, K., Kohno, T., Tsuta, K., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.002 · Cited by 26
West, H., Oxnard, G. R., & Doebele, R. C. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e272 · Cited by 24
Chelabi, S., Mignard, X., Leroy, K., Monnet, I., Brosseau, S., Théou–Anton, N., Massiani, M.-A., Friard, S., Duchemann, B., Fabre, E., et al. (2021) · Cancers · doi:10.3390/cancers13205132 · Cited by 20
Reichegger, H., Jochum, W., Förbs, D., Hader, C., & Früh, M. (2016) · Oncology Research and Treatment · doi:10.1159/000446759 · Cited by 18
EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
Hochmair, M. J., Holzer, S., Filipits, M., Mohn-Staudner, A., Arns, M., Errhalt, P., Absenger, G., Koller-Herzog, U., Setinek, U., Haslbauer, F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e20572 · Cited by 3
Cited by
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Self-citationLi, T., Kung, H.-J., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 518
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403614 · Cited by 458
Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Wang, J., Azuma, K., Juan-Vidal, O., Cobo, M., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.117 · Cited by 440
Metadata
- Authors
- Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., DeCamp, M., Dilling, T. J., Dowell, J., Gettinger, S., Grotz, T. E., Gubens, M. A., Hegde, A., Lackner, R. P., Lanuti, M., Lin, J., Loo, B. W., Lovly, C. M., Maldonado, F., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G. A., Pacheco, J. M., Patel, S. P., Riely, G. J., Riess, J., Schild, S. E., Shapiro, T. A., Singh, A. P., Stevenson, J., Tam, A., Tanvetyanon, T., Yanagawa, J., Yang, S. C., Yau, E., Gregory, K., & Hughes, M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2022-05
- Volume
- 20
- Issue
- 5
- Pages
- 497-530
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4280533169
- Cited by
- 1,392
- References
- 217
- FWCI
- 177.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.